Susquehanna International Group
VBIV

Susquehanna International Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Susquehanna International Group’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,293
Closed -$49K – 14015
2022
Q3 		$49K Sell
2,293
-367
-14% -$9.89K ﹤0.01% 12224
2022
Q2 		$65K Sell
2,660
-3,047
-53% -$104K ﹤0.01% 11818
2022
Q1 		$284K Sell
5,707
-8,606
-60% -$425K ﹤0.01% 10403
2021
Q4 		$1M Sell
14,313
-5,197
-27% -$438K ﹤0.01% 7280
2021
Q3 		$1.82M Sell
19,510
-7,950
-29% -$755K ﹤0.01% 6045
2021
Q2 		$2.76M Sell
27,460
-6,433
-19% -$627K ﹤0.01% 5208
2021
Q1 		$3.16M Buy
33,893
+11,036
+48% +$1.12M ﹤0.01% 4840
2020
Q4 		$1.89M Sell
22,857
-11,486
-33% -$979K ﹤0.01% 5222
2020
Q3 		$2.95M Buy
34,343
+18,866
+122% +$2.2M ﹤0.01% 3887
2020
Q2 		$1.44M Buy
+15,477
New +$853K ﹤0.01% 5112

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group's VBIV Position: Q3 2023 in Review

Susquehanna International Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2023, closing a stake of 12,725 shares — an estimated $41.9K sold.

Susquehanna International Group first reported a position in VBIV in Q4 2016 and held it in 21 quarters. The position peaked at $5.68M in Q1 2021. 37 funds tracked by Wall St. Rank hold VBIV as of Q3 2023.

  • Susquehanna International Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2023 after selling out during the quarter.
  • Susquehanna International Group sold 12,725 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2023, an estimated $41.9K.
  • Susquehanna International Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2016 and held it in 21 quarters.
  • Susquehanna International Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $5.68M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2023.

Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.